Cite
Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection
MLA
Bradley, John S., et al. “Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.” The Pediatric Infectious Disease Journal, vol. 37, no. 11, Nov. 2018, pp. 1130–36. EBSCOhost, https://doi.org/10.1097/INF.0000000000002170.
APA
Bradley, J. S., Ang, J. Y., Arrieta, A. C., Larson, K. B., Rizk, M. L., Caro, L., Yang, S., Yu, B., Johnson, M. G., & Rhee, E. G. (2018). Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. The Pediatric Infectious Disease Journal, 37(11), 1130–1136. https://doi.org/10.1097/INF.0000000000002170
Chicago
Bradley, John S., Jocelyn Y. Ang, Antonio C. Arrieta, Kajal B. Larson, Matthew L. Rizk, Luzelena Caro, Shan Yang, Brian Yu, Matthew G. Johnson, and Elizabeth G. Rhee. 2018. “Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.” The Pediatric Infectious Disease Journal 37 (11): 1130–36. doi:10.1097/INF.0000000000002170.